prostatic growth. In addition, the human prostatic cancer cell lines LNCaP and DU-145 express at least one type of activin type I receptors, as demonstrated by reverse transcription polymerase chain reaction (RT-PCR) (Batres et al, 1995; Furst et al, 1995; Ying et al, 1995) . Recently, the presence of immuno-reactive inhibin/activin subunits was demonstrated in the rat prostate (Risbridger et al, 1996) and in prostatic tissue of men with benign prostatic hyperplasia (Thomas et al, 1998) . Finally, activin has an inhibitory effect on the growth of the human prostatic carcinoma cancer cell line LNCaP (Dalkin et al, 1996; Wang et al, 1996b; McPherson et al, 1997; Zhang et al, 1997a Zhang et al, , 1997b , indicating that the activin/inhibin system can play a role in the control of prostate epithelial cell proliferation. Changes in expression of inhibin/activin subunits, activin receptors or the activin-binding protein follistatin may therefore influence growth of prostate epithelial cells. On the basis of these data, we hypothesized that transcript levels for activin β-subunits or activin receptors might be lower in tumour material when compared to normal prostatic tissue (in the case of clinical material) and in androgenindependent cell lines and xenografts when compared to their androgen-dependent counterparts.
Therefore we measured the mRNA expression levels of activin type I and type II receptors, of inhibin α-and inhibin/activin β-subunits and of follistatin by RNAase protection analyses in androgen-dependent and androgen-independent human prostatic xenografts, in various sublines of the human prostatic cell line LNCaP, and in non-malignant and malignant prostate tissues.
MATERIALS AND METHODS

Cell lines, xenografts and primary tumours
The androgen-dependent LNCaP-FGC (FGC) and the androgenindependent LNCaP-r (R) and LNCaP-LNO (LNO) (Horoszewicz et al, 1983) . FGC and LNO (van Steenbrugge et al, 1991) were kindly provided by Dr JS Horoszewicz, subline FGC being identical to the LNCaP line available through the American Type Culture Collection (ATCC). The R-subline (Hasenson et al, 1985) was a gift from Dr M Hasenson (Karolinska Institute, Sweden). FGC and R were routinely cultured in RPMI medium, supplemented with 10% fetal calf serum (FCS), glutamine and antibiotics. For culturing LNO, regular FCS was replaced by 5% dextran-coated charcoal (DCC)-treated, i.e. androgen-depleted, FCS. In order to study effects of activin on cell proliferation, R cells were grown for 5 days in DCC-treated medium with the indicated amounts of activin A (Innogenetics, Ghent, Belgium). Growth was determined with a colourimetric (MTT) assay, as described earlier (Romijn et al, 1988) . The prostate tumour xenografts used in this study are the androgen-dependent PC-82 (Hoehn et al, 1980) , PC-295, PC-310, PC-329 (van Weerden et al, 1996) and the androgen-independent PC-133, PC-135 (van Steenbrugge, unpublished results), PC-324, PC 339 and PC-374 (van Weerden et al, 1996) .
Primary tumour material was obtained after radical prostatectomy in 24 patients. From 20 sections of paraffin-embedded tissue to be used for RNA isolation, sections 1, 10 and 20 were used for histological examination. Based upon these observations, 12 samples were classified as normal (i.e. non-malignant) and 12 as carcinoma (Gleason scores: G-6 (1), G-7 (1), G-8 (5), G-9 (2), G-10 (3)).
RNA isolation and RNAase protection assays
Frozen tissue (-80°C) was pulverized in liquid nitrogen, followed by RNA isolation using TRIzol reagent (Gibco-BRL, Gaithersburg, MD, USA), according to the manufactures protocol. For the cell lines, cells were washed once in phospate-buffered saline (PBS) after which TRIzol reagent was added to the culture flasks. RNA was dissolved in RNAase-free water and its concentration and purity were determined by optical density measurement at 260 and 280 nm.
cDNA clones for the specific human transcripts (van Schaik et al, 1997) were digested with appropriate restriction enzymes and 32 P-labelled RNA probes were made by transcription in the presence of 32 P-UTP, using T3 or T7 RNA polymerase (Stratagene, La Jolla, CA, USA). The cRNA probes protect nucleotides 126-411 for the inhibin α-subunit (Mayo et al, 1986) , nucleotides 702-946 for the βA-subunit (Mason et al, 1986) , nucleotides 845-1073 for the βB-subunit (Mason et al,1986 ) and nucleotides 508-819 for the follistatin transcript. The latter probe therefore detects mRNAs, which can be translated into both follistatin-288 and follistatin-315. For the activin receptors, the cRNA probes protect nucleotides 1482-1692 for ActRIA (ten Dijke et al, 1993) , nucleotides 191-361 for ActRIB (GenBank, accession number Z22536), nucleotides 132-791 for ActRIIA (Donaldson et al, 1992) and nucleotides 429-947 for ActRIIB (Hildén et al, 1994) . For human γ-actin, a probe corresponding to nucleotides 1207-1337 (Erba et al, 1986 ) was used. RNAase protection assays were performed as described by Sambrook et al (1989) . RNAase treatment was performed using SIgnal (% of control)
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Figure 2 Effect of activin on the proliferation of the androgen-independent cell line LNCaP-R. Cells were grown for 5 days in DCC-treated medium with the indicated amounts of activin (n = 8). Growth was determined in a colourimetic (MTT) assay, and plotted relative to cells grown in DCC, which was set at 100%. Significant differences (P < 0.05) in proliferation from control (DCC without activin) are marked with an asterisk 100 U ml -1 RNAase T1 (Boehringer, Mannheim, Germany) in combination with 10 µg ml -1 RNAase A (Boehringer). Hybridization temperature was 42°C. Routinely, 5 µg RNA was analysed. In each run, positive and negative controls were included. Results were quantified using a PhosphorImager (Molecular Dynamics/B&L Systems, Maarssen, The Netherlands) and data are expressed relative to γ-actin. Unless stated otherwise, mean values ± s.e.m. are given and comparisons between groups were made using the Mann-Whitney U-test. P-values < 0.05 were interpreted as indicating a significant difference.
RESULTS
LNCaP sublines
In three independent experiments, we found that the androgendependent FGC-and the androgen-independent R-and LNO-cell lines expressed activin type I (ActRIA and ActRIB) and type II (ActRIIA and ActRIIB) receptor mRNAs at comparable levels ( Figure 1 ). For ActRIIA mRNA expression, significantly higher levels were found in the R-line when compared to the FGC-and LNO-lines. Furthermore, a small but significant difference was observed between the FGC-and LNO-line for the ActRIIB mRNA levels. The FGC and LNO cell lines express inhibin/activin βB-subunit mRNA, while in the R-line βB-subunit mRNA was virtually absent. We found low inhibin/activin βA-subunit mRNA levels in all three sublines, while expression of inhibin α-subunit mRNA was at the detection limit of our assay. Follistatin mRNA expression was not detectable.
The functionality of the activin signalling pathway in the LNCaP sublines was investigated by growing the androgenindependent R cells in the presence of varying amounts of activin. The cells were significantly inhibited in their proliferation when incubated on DCC-medium in the presence of activin (P < 0.05) (Figure 2 ).
Prostatic carcinoma xenografts
In tissue specimens of well defined androgen-dependent and androgen-independent xenograft models, we quantitatively investigated expression of inhibin/activin subunits, activin receptors and follistatin mRNAs. All xenografts studied expressed 
(12) (7) (11) (6) (5)
(11) (11) activin type I (ActRIA and ActRIB) and type II (ActRIIA and ActRIIB) receptors (Figure 3 ). Inhibin/activin βA-subunit expression was not detectable in the androgen-dependent xenografts, while of the androgen-independent xenografts only PC-324 showed a low level of expression. Inhibin/activin βB-subunit mRNA, however, was abundantly expressed in the androgendependent xenografts. This expression level was found to be significantly lower (P < 0.05) in the androgen-independent tumours. Follistatin mRNA was expressed with a large variation, ranging from undetectable to a relatively high (16.8 relative units (RU)) expression in the androgen-independent xenograft PC-324. We could not detect inhibin α-subunit mRNA expression in the xenograft samples.
Clinical prostatic carcinomas
In all clinical prostate samples investigated, expression of activin type I (ActRIA and ActRIB) and type II (ActRIIA) receptors was found, while ActRIIB expression was detected in four of seven non-malignant prostatic tissues and in nine of eleven samples of prostate carcinomas. The carcinomas expressed significantly lower levels of ActRIB mRNA when compared to the non-malignant tissues (15.3 ± 3.0 vs 26.0 ± 3.1 RU respectively; P < 0.05) (Figure 4 ). Inhibin/activin βA-and βB-subunit mRNAs were expressed at comparable levels in non-malignant and carcinomatous samples. Inhibin α-subunit mRNA expression was low or not detectable. Follistatin mRNA expression was generally found at low expression levels, and was significantly lower in the carcinomas when compared to non-malignant tissue (P < 0.05).
DISCUSSION
Activin receptors
We measured mRNA expression levels of activin receptors type IA, IB and type IIA, IIB in human prostate cancer cells, either in culture, in xenografts or clinical tissues. In the three sublines of LNCaP, significant differences were observed in the expression of ActRIIA and ActRIIB mRNA. In prostatic carcinoma xenografts we demonstrated expression of all known activin type I and activin type II receptors. No significant differences in expression of activin receptors were observed when androgen-dependent and androgen-independent xenografts were compared. In tissue obtained after radical prostatectomy, in which the neoplastic grade of the samples was determined microscopically to range from nonmalignant to Gleason grade 10, expression of ActRIA and ActRIB mRNA was found. Transcript levels for ActRIB were significantly lower in the carcinomas when compared to the non-malignant tissues. This implies a decreased sensitivity to growth inhibition by activin: it was shown that ActRIB is responsible for inhibition of proliferation by activin, rather than ActRIA (Cárcamo et al, 1994) . No correlation was observed between Gleason grade and ActRIB mRNA levels within this limited series. Expression of ActRIIA mRNA was demonstrated in all samples, but ActRIIB mRNA transcripts were undetectable in a number of them. These results corroborate and significantly extend previous reports using the reverse transcriptase polymerase chain reaction (RT-PCR) for the qualitative detection of expression of activin receptors in human prostate cancer cell lines (Batres et al, 1995; Furst et al, 1995; Dalkin et al, 1996) , and are in line with the detection of ActRIIA and IIB transcripts in the rat prostate (Feng et al, 1993) and recently of ActRIIA mRNA in benign prostate hyperplasia (Thomas et al, 1998) . Remarkably, the relative signal for ActRIA was lower than that for ActRIB in the LNCaP cell lines while in most of the xenografts relatively more ActRIA was expressed than ActRIB. In the clinical prostate samples expression of ActRIA and of ActRIB were comparable; this may have been caused by the presence of stromal tissue in these samples. The combined expression of type I and type II receptors in human prostatic epithelial cells indicates that a functional activin receptor complex can be formed in the presence of activin, thereby enabling activin to have an effect on these cells. We confirmed this in androgen-independent R cells. These results are in line with data reported on androgen-dependent LNCaP cells (Dalkin et al, 1996; Wang et al, 1996b ), but differ with results obtained with the androgen-independent cell lines PC3 and DU-145 (Ying et al, 1997) . Possibly, the defect in the retinoblastoma gene product in DU-145 (Rubin et al, 1991) and the expression of relatively large amounts of follistatin by PC3 cells (Wang et al, 1996a) or the presence of a mutated p53 gene in PC3 cells (Rubin et al, 1991) are responsible for this lack of response to activin treatment.
Activin/inhibin subunits and follistatin
In addition to activin receptor expression, we quantified mRNA levels for inhibin/activin β-subunits in prostate tumour cell lines, in prostate tumour xenografts and in samples of non-malignant and malignant prostatic tissues. Expression of predominantly βB-subunit mRNA was found in the FGC cell line, but this expression was virtually absent in the androgen-independent R-line. Decreased production of activin might lead to a growth advantage; the R-line is indeed still sensitive to growth inhibition by activin (Figure 2) . However, the other androgen-independent cell line in our study (LNO) did not show this decreased βB-subunit expression, indicating that not all androgen-independent cell lines have low levels of activin. For the FGC-subline, we found variable results for inhibin/activin βB-subunit expression in three independent experiments, resulting in a relative large variation, which cannot be explained at this moment. The three independent experiments were performed with relatively large time intervals; therefore we hypothesize that, at least for this subline, variable conditions of e.g. cell density or passage number, may have caused the observed variation. Qualitative expression of βB-subunit mRNA in LNCaP has been reported earlier, using RT-PCR (Batres et al, 1995; Furst et al, 1995) . Dalkin et al (1996) investigated the effect of endogenous activin on proliferation of LNCaP-FGC cells by addition of follistatin and found an increase in proliferation after 24 h treatment confirming endogenous activin production. Low, but detectable inhibin α-subunit mRNA levels were found in the RNAase protection assay for the LNCaP sublines, whereas the absence of inhibin α-subunit mRNA in LNCaP cells using RT-PCR has been reported earlier (Batres et al, 1995) . It is unclear whether this difference is caused by subtle differences in properties of the LNCaP cell lines used, or culture conditions applied. On the other hand, the RT-PCR assay may not have functioned optimally, which is difficult to assess due to the absence of a positive control for the inhibin α-subunit mRNA RT-PCR (Batres et al, 1995) . Inhibin immunoreactivity was found to be absent in LNCaP cells (Batres et al, 1995) , suggesting that inhibin production in FGC cells is indeed very low. In the xenografts, βA-subunit expression was not detectable in the androgen-dependent samples and was only detected at low levels in one out of three androgenindependent tumours. RNAase protection will only measure expression in the epithelial component of the xenografts since stromal cells express the murine genes which, with the exception of ActRIIA mRNA, are not protected by the human cRNA probes (RHN van Schaik, unpublished results) . This suggests that the stromal cells may be responsible for the inhibin βA-subunit mRNA expression in the prostate. The androgen-independent xenografts had significantly lower expression levels of inhibin/activin βB-subunit mRNA when compared to the androgen-dependent samples, indicating a decrease in activin production with increasing malignancy. In the clinical samples we found a relatively high expression of both βA-and βB-subunit transcripts. Inhibin α-subunit mRNA levels in non-malignant and malignant prostate tissues were low or undetectable as determined by RNAase protection. Using in situ hybridization and immunohistochemistry on BPH-and prostate cancer samples, expression of inhibin α-subunit mRNA was found in prostate epithelial and basal cells, which was absent in malignant regions of tissue from men with high grade prostate cancer ). We did not find a significant difference in the expression of inhibin α-subunit transcript levels when non-malignant (0.3 ± 0.3 RU) and tumour samples (0.4 ± 0.2 RU) were compared, although this may be due to the very low expression levels detected in our study. We found a significantly higher expression of follistatin mRNA in the non-malignant samples when compared to the carcinomatous tissues. Because follistatin mRNA expression was undetectable by RNAase protection in the LNCaP sublines, follistatin might be expressed in stromal cells rather than in the epithelial cells. In fact, follistatin immunoreactivity was recently reported to be localized in fibroblastic stroma (Thomas et al, 1998) . Human follistatin mRNA expression was also found in three out of nine xenografts studied, indicating that the epithelial cells are also capable of expressing follistatin mRNA. In addition, the human prostatic carcinoma cell line PC3 expresses large amounts of follistatin (Wang et al, 1996a) while also follistatin mRNA could be detected in LNCaP cells using RT-PCR (Dalkin et al, 1996) . All in all, these data indicate that prostate epithelial cells can express follistatin, and suggest that the expression level in LNCaP cells is relatively low.
Our results on mRNA expression indicate that autocrine growth control by activin can occur in the prostate, and that malignant cells may escape growth inhibition by activin by a decrease in mRNA expression levels for the activin βB-subunit or for the activin receptor type IB. Decreased activin signalling may lead to increased cell proliferation and inhibition of apoptosis of prostate epithelial cells (Zhang et al, 1997a) , thereby facilitating prostate tumour development. Future experiments need to establish to what extent the differences found in mRNA levels can be translated to the protein level and can lead to differences in the behaviour of the tumours.
